Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.
Identifieur interne : 001462 ( Ncbi/Merge ); précédent : 001461; suivant : 001463Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.
Auteurs : Jun Huang [République populaire de Chine] ; Rui Ma ; Chang-You WuSource :
- Vaccine [ 0264-410X ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Femelle, Lymphocytes T CD4+ (immunologie), Lymphocytes T CD8+ (immunologie), Mémoire immunologique (immunologie), Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Vaccins à ADN (immunologie), Virus du SRAS (immunologie).
- MESH :
English descriptors
- KwdEn :
- Animals, CD4-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (immunology), Female, Immunization, Secondary, Immunologic Memory (immunology), Mice, Mice, Inbred BALB C, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Vaccines, DNA (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Vaccines, DNA, Viral Vaccines.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Immunologic Memory, SARS Virus, Severe Acute Respiratory Syndrome.
- Animals, Female, Immunization, Secondary, Mice, Mice, Inbred BALB C.
Abstract
An effective vaccine for severe acute respiratory syndrome (SARS) will probably require the generation and maintenance of both humoral and cellular immune responses. It has been reported that after natural infection in humans and immunization in animals with SARS-CoV vaccine, antibody is produced and persistent for a long period of time. In the present study, mice were immunized i.m. with SARS-CoV S DNA vaccine, and three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses when the cells were stimulated in vitro with a pool of peptides overlapping entire SARS spike protein. The results show that prime-immunization with SARS-CoV S DNA vaccine can induce both CD4(+) and CD8(+) T cell responses. Boosting with the same vaccine enhances CD4(+) and CD8(+) T cell responses in both lymphoid and nonlymphoid organs and were persistent over two months. The SARS-CoV S-specific CD4(+) and CD8(+) T cells were CD62L(-), a marker for memory cells, and -30 to 50% of the cells expressed IL-7Ralpha (CD127), a marker for the capacity of effector cells to develop into memory cells. In addition, immunization with the DNA vaccine elicited high levels of antibody production. Taken together, these data demonstrate that immunization with SARS-CoV S DNA vaccine can generate antigen-specific humoral and cellular immune responses that may contribute to long-term protection.
DOI: 10.1016/j.vaccine.2006.03.058
PubMed: 16621188
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002270
- to stream PubMed, to step Curation: 002270
- to stream PubMed, to step Checkpoint: 002151
Links to Exploration step
pubmed:16621188Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.</title><author><name sortKey="Huang, Jun" sort="Huang, Jun" uniqKey="Huang J" first="Jun" last="Huang">Jun Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Zhongshan Medical School University, #74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Zhongshan Medical School University, #74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080</wicri:regionArea><wicri:noRegion>Guangdong Province 510080</wicri:noRegion></affiliation></author><author><name sortKey="Ma, Rui" sort="Ma, Rui" uniqKey="Ma R" first="Rui" last="Ma">Rui Ma</name></author><author><name sortKey="Wu, Chang You" sort="Wu, Chang You" uniqKey="Wu C" first="Chang-You" last="Wu">Chang-You Wu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16621188</idno><idno type="pmid">16621188</idno><idno type="doi">10.1016/j.vaccine.2006.03.058</idno><idno type="wicri:Area/PubMed/Corpus">002270</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002270</idno><idno type="wicri:Area/PubMed/Curation">002270</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002270</idno><idno type="wicri:Area/PubMed/Checkpoint">002151</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002151</idno><idno type="wicri:Area/Ncbi/Merge">001462</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.</title><author><name sortKey="Huang, Jun" sort="Huang, Jun" uniqKey="Huang J" first="Jun" last="Huang">Jun Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Zhongshan Medical School University, #74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Zhongshan Medical School University, #74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080</wicri:regionArea><wicri:noRegion>Guangdong Province 510080</wicri:noRegion></affiliation></author><author><name sortKey="Ma, Rui" sort="Ma, Rui" uniqKey="Ma R" first="Rui" last="Ma">Rui Ma</name></author><author><name sortKey="Wu, Chang You" sort="Wu, Chang You" uniqKey="Wu C" first="Chang-You" last="Wu">Chang-You Wu</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>CD4-Positive T-Lymphocytes (immunology)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Female</term><term>Immunization, Secondary</term><term>Immunologic Memory (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Vaccines, DNA (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Lymphocytes T CD4+ (immunologie)</term><term>Lymphocytes T CD8+ (immunologie)</term><term>Mémoire immunologique (immunologie)</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T CD4+</term><term>Lymphocytes T CD8+</term><term>Mémoire immunologique</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term><term>CD8-Positive T-Lymphocytes</term><term>Immunologic Memory</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Immunization, Secondary</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An effective vaccine for severe acute respiratory syndrome (SARS) will probably require the generation and maintenance of both humoral and cellular immune responses. It has been reported that after natural infection in humans and immunization in animals with SARS-CoV vaccine, antibody is produced and persistent for a long period of time. In the present study, mice were immunized i.m. with SARS-CoV S DNA vaccine, and three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses when the cells were stimulated in vitro with a pool of peptides overlapping entire SARS spike protein. The results show that prime-immunization with SARS-CoV S DNA vaccine can induce both CD4(+) and CD8(+) T cell responses. Boosting with the same vaccine enhances CD4(+) and CD8(+) T cell responses in both lymphoid and nonlymphoid organs and were persistent over two months. The SARS-CoV S-specific CD4(+) and CD8(+) T cells were CD62L(-), a marker for memory cells, and -30 to 50% of the cells expressed IL-7Ralpha (CD127), a marker for the capacity of effector cells to develop into memory cells. In addition, immunization with the DNA vaccine elicited high levels of antibody production. Taken together, these data demonstrate that immunization with SARS-CoV S DNA vaccine can generate antigen-specific humoral and cellular immune responses that may contribute to long-term protection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16621188</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>23</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.</ArticleTitle><Pagination><MedlinePgn>4905-13</MedlinePgn></Pagination><Abstract><AbstractText>An effective vaccine for severe acute respiratory syndrome (SARS) will probably require the generation and maintenance of both humoral and cellular immune responses. It has been reported that after natural infection in humans and immunization in animals with SARS-CoV vaccine, antibody is produced and persistent for a long period of time. In the present study, mice were immunized i.m. with SARS-CoV S DNA vaccine, and three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses when the cells were stimulated in vitro with a pool of peptides overlapping entire SARS spike protein. The results show that prime-immunization with SARS-CoV S DNA vaccine can induce both CD4(+) and CD8(+) T cell responses. Boosting with the same vaccine enhances CD4(+) and CD8(+) T cell responses in both lymphoid and nonlymphoid organs and were persistent over two months. The SARS-CoV S-specific CD4(+) and CD8(+) T cells were CD62L(-), a marker for memory cells, and -30 to 50% of the cells expressed IL-7Ralpha (CD127), a marker for the capacity of effector cells to develop into memory cells. In addition, immunization with the DNA vaccine elicited high levels of antibody production. Taken together, these data demonstrate that immunization with SARS-CoV S DNA vaccine can generate antigen-specific humoral and cellular immune responses that may contribute to long-term protection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, Zhongshan Medical School University, #74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chang-you</ForeName><Initials>CY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16621188</ArticleId><ArticleId IdType="pii">S0264-410X(06)00384-7</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2006.03.058</ArticleId><ArticleId IdType="pmc">PMC7115633</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2003 Dec 15;198(12):1797-806</Citation><ArticleIdList><ArticleId IdType="pubmed">14662907</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drugs. 2005;65(17):2437-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16296870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 2004 Jun;199:144-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15233732</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Apr 25;335(1):34-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15823604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2005 Oct 1;175(7):4686-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16177116</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Mar 25;328(4):979-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15707974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2005 Jul 4;202(1):123-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15983064</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Aug 15;23(35):4385-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16005746</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 2004 Jun;199:126-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15233731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2003 Dec;4(12):1191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14625547</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2003 Sep;4(9):835-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12942084</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2002 Jan 15;168(2):597-603</Citation><ArticleIdList><ArticleId IdType="pubmed">11777951</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2002 Sep;3(9):852-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12172546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2005 Jul 1;175(1):591-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15972696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Feb 20;421(6925):852-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12594515</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2003 Apr;3(4):269-79</Citation><ArticleIdList><ArticleId IdType="pubmed">12669018</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2003 Mar;4(3):225-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12563257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Ma, Rui" sort="Ma, Rui" uniqKey="Ma R" first="Rui" last="Ma">Rui Ma</name><name sortKey="Wu, Chang You" sort="Wu, Chang You" uniqKey="Wu C" first="Chang-You" last="Wu">Chang-You Wu</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Huang, Jun" sort="Huang, Jun" uniqKey="Huang J" first="Jun" last="Huang">Jun Huang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001462 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001462 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16621188
|texte= Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16621188" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |